image credit: Freepik

Decibel Therapeutics Announces Pricing of Initial Public Offering

February 12, 2021

Via: BioSpace

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the pricing of its initial public offering of 7,062,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Decibel. In addition, Decibel has granted the underwriters a 30-day option to purchase up to an additional 1,059,300 shares of common stock at the public offering price, less underwriting discounts and commissions.

Read More on BioSpace